Member
Striker
Yeah it was poorly worded really. I think the doses were reported in that way due to uncertainty about if you'd need just one or if you'd need a booster, but the Pfizer vaccine has only been trialed with a booster so should have been clearer.Thanks. I suppose it's partly a case of semantics. If they had just said "enough for 15 million people" there wouldn't be that question.
I think there's also more to worry about than just supply chain. I suspect there's going to be a lot of arguing (at a macro and micro level) over who gets it first. I know in general they're saying people at risk and people on the front line, but in both of those categories there's going to be issues. For example, do Firemen count as front line? Do the Police? And once you've decided that the Police do count, are we talking the constables who are actually out and about, or the chief inspectors who spend their time behind a desk? I think we all know who should, but we also know who will.
Another question for you: the headlines also said this vaccine is 90% effective. How does that compare with other vaccines for other viruses?
I'll reply about prioritisation in a minute, because GNH asked the same thing.
It's apples and oranges to compare different vaccines, but 90% is really really good. Flu vaccines for example are now evaluated in the population rather than in large phase 3 studies, so the results you get are from population epidemiology and real world use, rather than from a study, as per this case. Note that the Pfizer vaccine has quite a novel method of action, so it's cutting edge and comparing it to other vaccines of other types isn't immediately helpful. 90% efficacy may not be achieved in the real world (people may not show for their second dose, for example) but that's a really good starting point to work from
I'm keen to know what it does for symptomatic COVID-19 as well, because if it reduces severity as well as avoids transmission then that's even better.
Last edited: